Search

Displaying results 3791 - 3800 of 7284 in total
  1. Drug

    Fluoxetine

    go.drugbank.com/drugs/DB00472
    ApprovedInvestigationalVet approved

    Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). … [A181673] It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies

    Products: FLUOXETIN 10 1A PHARMA, FLUOXETIN 20 1A PHARMA
  2. Drug

    Ulobetasol

    go.drugbank.com/drugs/DB00596
    Approved

    Ulobetasol is a highly potent corticosteroid.[A215597] It is structurally related to [clobetasol]. … [L15047,L15052,L15102] Ulobetasol was granted FDA approval on 17 December 1990.[L15047]

  3. Drug

    Clobetasol propionate

    go.drugbank.com/drugs/DB01013
    ApprovedInvestigational

    [A190936] Clobetasol Propionate was granted FDA approval on 27 December 1985.[L11809] … Clobetasol propionate is a prednisolone derivative with higher specificity for glucocorticoid receptors than mineralocorticoid receptors.

    Mixtures: FOLISTER COMPLEX HAIR LOTION (R), FOLISTER COMPLEX HAIR LOTION (R)
  4. Drug

    Temsirolimus

    go.drugbank.com/drugs/DB06287
    ApprovedInvestigational

    Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007. … Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  5. Drug

    Brivaracetam

    go.drugbank.com/drugs/DB05541
    ApprovedInvestigational

    Briviact received FDA approval on February 19, 2016 [L760]. … Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam [A19184].

  6. Drug

    Luliconazole

    go.drugbank.com/drugs/DB08933
    ApprovedInvestigational

    It was approved by the FDA (USA) in November 2013 and is marketed under the brand name Luzu. Luliconazole is also approved in Japan. … Luliconazole is a topical antifungal agent that acts by unknown mechanisms but is postulated to involve altering the synthesis of fungi cell membranes.

  7. Drug

    Vemtoberant

    go.drugbank.com/drugs/DB21607
    Investigational

    Vemtoberant has a monoisotopic molecular weight of 619.2 Da. … Vemtoberant is a small molecule drug.

  8. Drug

    Delocamten

    go.drugbank.com/drugs/DB21711
    Investigational

    Delocamten has a monoisotopic molecular weight of 377.16 Da. … Delocamten is a small molecule drug.

  9. Drug

    Turoctocog alfa pegol

    go.drugbank.com/drugs/DB14738
    ApprovedInvestigational

    The essential difference between turoctocog alfa and N8-GP, however, is the specific attachment of a 40-kDa polyethylene glycol (PEG) group to a specific _O_-glycan in the truncated B-domain of the general … As such, turoctocog alfa pegol is a valuable expansion to the drug therapies available for treating hemophilia A as it ultimately provides a less burdensome and more convenient dosing regimen for patients

  10. Target

    Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial

    go.drugbank.com/bio_entities/BE0002254
    TargetHumans

    Iron-sulfur protein (IP) subunit of the succinate dehydrogenase complex (mitochondrial respiratory chain complex II), responsible for transferring electrons from succinate to ubiquinone (coenzyme Q) (PubMed

    Synonyms: Iron-sulfur subunit of complex II